CLARITY Imaging Study

Glaucoma Clinical Trial

— CLARITY  

Official title:

CLARITY Imaging Study: The Effect Of Cross-linked Sodium Hyaluronate On The Quality Of Optical Coherence Tomography Imaging

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03758859
• Other study ID #: 18SM4868
• Status: Recruiting
• Phase: N/A
• Start date: April 12, 2019
• Est. completion date: October 31, 2019

Study information

• Verified date: September 2019
• Source: Imperial College London
• Contact: Serge Miodragovic
• Phone: +442033123206
• Email: serge.miodragovic1[@]nhs.net
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

OCT image quality is necessary to provide accurate diagnostic information to ophthalmologists. The increasing resolution of imaging techniques will require ever more high standards of optical transmission through the cornea and tear film. Given that lubricant drops can improve optical transmission through the cornea, this study will attempt to quantify this. The primary objective is to assess the effect of cross-linked sodium hyaluronate on OCT image quality compared to the effect of blinking alone.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: October 31, 2019
• Est. primary completion date: October 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients subjectively deemed to have poor image quality by the photographer

Exclusion Criteria:

• Patients with a known adverse reaction to any of the constituents of the XLHA

• Patients wearing contact lenses

• Patients who have used eyedrops in the past 2 hours

Related Conditions & MeSH terms

• Glaucoma

Intervention

Other:
• sodium hyaluronate eyedrops
sodium hyaluronate eyedrops administered - route ocular -topical

Locations

Country	Name	City	State
United Kingdom	Western Eye Hospital	London

Sponsors (1)

Lead Sponsor	Collaborator
Imperial College London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clarity of retinal images obtained by Optical Coherence Tomography.	Signal strength of OCT scan	immediately after the administration of drops.